Ross Cummings’ Post

Join us for an informative #BPIAskTheExpert webinar with BioProcess International, where we will explore upstream process intensification. This session is a must-attend for anyone looking to maximize their mAbs, cell therapy, or gene therapy manufacturing. Charles Hill, field applications scientist from Repligen will discuss how the XCell® ATF System and KrosFlo® TFDF® System revolutionize upstream applications, offering real-world case studies on increasing productivity and reducing costs. Webinar Title: More Product Faster: Maximize mAbs, Cell Therapy, and Gene Therapy Production with Upstream Process Intensification Date: July 25, 2024 Time: 11 am EDT | 8 am PDT | 5 pm CEST Duration: 30 minutes Key Takeaways: * Achieve 2-10x higher titers with the XCell ATF System. * Accelerate speed to market with ATF and TFDF technology. * Learn about scaling from process development to commercial manufacturing. Don't miss out on this opportunity to enhance your production capabilities. Register now and spread the word to your network! https://lnkd.in/gyGHX8ib #KrosFloTFDF, #N-1seedtrain,#lentivirus, #Viralvector, #Perfusion, #Genetherapy #XCellATF #IntensificationStartsHere #ProcessIntensification #UpstreamBioprocessing #bioproduction #processdevelopment #cellculture #bioprocessing #CDMO #biomanufacturing #celltherapy #biologics #antibodies #biosimilars

🧬Explore the strategic insights from the BioTech Industry Outlook 2024 and discover how to capitalize on emerging trends in cell therapy, gene therapy, and AI-driven drug discovery. Leverage the future of #biotech with insights from MarketsandMarkets. To explore the top trends reshaping the industry in 2024, click here. https://lnkd.in/dsEhiX4J #healthcare #globaltrends #marketanalysis #medtech #healthcarerevolution #futureofhealthcare #marketsandmarkets

Regeneron CEO, Leonard Schleifer, recently shared his belief that "associating genes with disease" will drive the entire pharmaceutical industry. This statement emphasizes the growing significance of gene therapy in the biotech industry. However, the question remains: what will have a more significant impact on the industry, AI or gene therapy? Share your thoughts in the comments below. Let's start a conversation on the future of biotech! #biotech #genetherapy #AI #pharmaceuticalindustry

Cell and Gene Therapy: Pioneering Change in Pharma 2024 In a recent survey, 18% of healthcare professionals predict Cell and Gene Therapy (CGT) will dominate the pharmaceutical landscape in 2024. This revolutionary approach manipulates cells and genes to address diseases at their roots, offering precision, personalization, and the potential for cures. The versatility of CGT spans genetic disorders to various cancers, marking a paradigm shift in healthcare. While challenges exist, including regulatory hurdles and manufacturing complexities, the industry is poised for transformative change. As the pharmaceutical landscape adapts to this era, the impact of CGT on patient care is set to be revolutionary.

🔥 Coming out of one of the Fireside Chat sessions at the 2024 ASGCT Annual Meeting is more on the need for guidelines, a framework of 'global regulatory convergence' in Cell and Gene Therapy, particularly in the development, manufacturing, and access. Leading the discussion is US #FDA's Marks, CBER Director. 🌎 Marks explained to the audience that varied countries' criteria for CGTs, from preclinical testing to manufacturing, make it difficult for patients in certain parts of the world to obtain treatments, particularly those in the rare disease space. Forward-looking: "Five to 10 years from now, Marks’ vision is that there will be enough global regulatory convergence “such that we can get to where we are currently with vaccines” internationally. “It would reduce regulatory burden.”" #ASGCT #CellAndGeneTherapy #CellTherapy #GeneTherapy #RegulatoryAffairs #Oversight #Innovation #Biotech #Healthcare

The biomanufacturing industry is undergoing significant growth due to advancements in cell and gene therapy. This has increased demand for specialized biomanufacturing facilities, leading to a surge in capital investment and scientific innovation. Unique infrastructure requirements, third-party service providers, and regional clustering are among the key trends driving the #RealEstate requirements for these #facilities. Check out the latest article from our #LifeSciences research team #CBRE #biomanufacturing #LifeSciences #RealEstate #FacilitiesManagement

For anyone working in cell and gene therapies, I highly recommend giving Scientist.com's latest article on streamlining IND applications a read! 🧬 This article offers a glimpse into how Scientist.com helps researchers efficiently manage IND applications for CGTs—from preclinical to clinical and CMC processes. We should be doing everything we can to accelerate bringing high-quality life-changing therapies to the clinic, and Scientist.com is playing a huge role in that. 🔗 Read more here: https://lnkd.in/e42ujB7N #CellTherapy #GeneTherapy #IND #RegulatoryAffairs #CMC #FasterScience

🚨Attention all 𝘐𝘯 𝘝𝘪𝘷𝘰 Cell and Gene Experts!🚨   ⏳Our 𝗹𝗼𝘄𝗲𝘀𝘁 𝗲𝗮𝗿𝗹𝘆𝗯𝗶𝗿𝗱 𝗼𝗳𝗳𝗲𝗿, with 𝘀𝗮𝘃𝗶𝗻𝗴𝘀 𝗼𝗳 𝘂𝗽 𝘁𝗼 $𝟭,𝟭𝟬𝟬 for the 𝟯𝗿𝗱 𝗜𝗻 𝗩𝗶𝘃𝗼 𝗖𝗲𝗹𝗹 𝗘𝗻𝗴𝗶𝗻𝗲𝗲𝗿𝗶𝗻𝗴 & 𝗚𝗲𝗻𝗲 𝗘𝗱𝗶𝘁𝗶𝗻𝗴 𝗦𝘂𝗺𝗺𝗶𝘁 expires this Friday, 22nd March.   Find out more in the full agenda - https://ter.li/t2sz0v   As promising pre-clinical and proof of concept results continue to emerge, we are thrilled to unite C-level executives, VPs, and directors from Capstan Therapeutics, Editas Medicine, Nanocell Therapeutics, Sanofi, and many more to explore every aspect of 𝘪𝘯 𝘷𝘪𝘷𝘰 cell and gene therapies and discuss various approaches to advance pipelines forward.   🔥Secure your incredible savings here - https://ter.li/axpwmz   Are you really willing to miss out on this once-a-year opportunity to join key players in discovery, pre-clinical, and translational fields for 𝗶𝗻𝘃𝗮𝗹𝘂𝗮𝗯𝗹𝗲 𝗻𝗲𝘁𝘄𝗼𝗿𝗸𝗶𝗻𝗴 𝗮𝗻𝗱 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀 into the future of cell and gene therapy?   #InVivoCellEngineeringandGeneEditingSummit

New promising option in #HF for the next future

Exciting news from our partners at Wilson Wolf Manufacturing, LLC! With ScaleReady, they just rolled out a $20M G-Rex Grant Program, designed to propel the advancement of cell and gene therapies. The program will reduce the barriers to entry for cell and gene therapy manufacturers and provide resources and services to help implement or optimize a highly efficient G-Rex® based cell manufacturing platform. It is open to all, and relevant for any cell and gene therapy entity that is moving toward, or already conducting, clinical manufacturing. Given our shared goal of scaling cell therapy treatments, it’s awesome to see this come to fruition. It is crucial to develop a simple process - so that it can be readily automated from there. Via our partnership, we are already collaborating to automate their G-Rex® bioreactors, so manufacturers can use the automated bioreactor without substantially changing their existing process. Check out the grant program and learn more about getting involved here: https://lnkd.in/eWesmsWJ #manufacturing #celltherapy #cellandgenetherapy #pharma #innovation